Noticias

Ozempic and Wegovy demand rose after Novo lowered prices to compete with generics.

The European stock markets were tracking lower, and oil prices were rising Friday following media re

PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.

Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish pharmaceutical giant. And both UBS and Citi are highlighting the pill's trajectory as the defining question for the company's medium-term outlook...

Novo's price cuts lifted Wegovy and Ozempic demand while cheaper GLP-1 therapies expanded India's obesity-drug market.

Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.

Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can Lilly compete with copies of its own drug?

Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly.

Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter 2026 earnings call on May 7. Chief Executive Officer Mike Exton said the company entered 2026 with o

If you are wondering whether Novo Nordisk stock is attractively priced right now, the key is to understand what the recent share price is actually implying about future expectations. The stock last closed at US$45.80, with recent returns of 8.5% over 7 days and 24.1% over 30 days, but a 27.0% decline over 1 year and a 42.7% decline over 3 years. These moves have come alongside ongoing attention on Novo Nordisk's role in pharmaceuticals and biotech, including its position in treatments that...

Novo Nordisk (CPSE:NOVO B) shocked the market with first quarter 2026 results, as its new oral Wegovy weight loss pill quickly surpassed 2 million US prescriptions and prompted a higher full year outlook. See our latest analysis for Novo Nordisk. The strong first quarter has triggered a sharp rebound in sentiment, with a 25.69% 1 month share price return and 8.54% 7 day gain. However, the year to date share price return of 10.52% and 1 year total shareholder return of 27.91% still point to a...

Novo now expects profit and sales declines of up to 12% this year, better than its earlier 13% forecast.

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Amazon will offer same-day delivery for Novo Nordisk's Ozempic pill.

Novo partnership deepens Amazon healthcare ambitions

Find insight on Amazon Pharmacy, Sanofi, Sunway Health and more in the latest Market Talks covering the health care sector.

Customers with a prescription can pick up the diabetes pill at select One Medical kiosks or have it delivered the same day for $149 a month

LONDON/COPENHAGEN, May 7 (Reuters) - Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricing pressure. Denmark's Novo, ‌which has struggled to keep pace with U.

Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S. Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format. The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market. Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a...

While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.

Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.

The pill era has ushered in a Wild-West-style land-grab for GLP-1 market share but the horizon seems to keep expanding.

Health care stocks were higher late Wednesday afternoon, with the NYSE Health Care Index increasing

Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% a

Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.

Novo Nordisk stock jumps as Q1 earnings and revenues beat estimates, fueled by strong Wegovy and Ozempic demand and a raised 2026 outlook.

Private Payrolls Increased More Than Expected